Immunotherapy of multiple sclerosis: where are we? Where should we go?
about
Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysisInferring relevant control mechanisms for interleukin-12 signaling in naïve CD4+ T cells.New approaches to investigating heterogeneity in complex traitsAutoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice.Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood.Glatiramer in the treatment of multiple sclerosisEffects of vaccination with altered Peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosisEarly stage and long term treatment of multiple sclerosis with interferon-betaCell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis.Immunological heterogeneity of multiple sclerosis in Sardinia and Sweden.Label-free detection of neuron-drug interactions using acoustic and Kelvin vibrational fields.Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta.Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro.[(11)C]DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model.
P2860
Q30902237-203358CB-03A2-4616-BC3C-DBABFDDC43BFQ34419693-BFB87A4E-CDD3-4203-A710-BFE934558ADCQ35200318-87CF9A76-04DD-4CB3-9468-8F7F02185F28Q35861182-F1C7D2C1-F161-4517-B03D-DACEDB18C93EQ36327377-81B1BAEB-C05E-4A4E-A82D-9DCD6BD541D1Q36370602-EA525949-0188-4A5F-9528-4EE27E475625Q36602220-0372CD35-B898-45EE-8B0C-48FCF396E29CQ36918770-F002ED8D-068F-4B81-978B-BB1B9A515D00Q37261686-B6274D1A-88DC-44A5-84B6-2B16EAC3353EQ37303237-0613EEC0-6A2D-41B1-BD9B-B62D6CFE2FB8Q40445781-6C7DCF45-E42E-433E-80D7-29BA73DA0C7FQ45283233-D34D4051-2051-4B3F-90A5-B81FAD0FF0ABQ48259980-7DCABEE8-C2FB-4259-8B33-96D17D7948FFQ51648083-C2E508C7-6AC4-4195-B846-A95A21244A07Q53017764-FF6C0543-98B7-4F75-9C14-5B10EDA60E2EQ53194305-2E549A6C-C7FE-484E-84B1-3ACE27B9604D
P2860
Immunotherapy of multiple sclerosis: where are we? Where should we go?
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Immunotherapy of multiple sclerosis: where are we? Where should we go?
@en
type
label
Immunotherapy of multiple sclerosis: where are we? Where should we go?
@en
prefLabel
Immunotherapy of multiple sclerosis: where are we? Where should we go?
@en
P2860
P356
P1433
P1476
Immunotherapy of multiple sclerosis: where are we? Where should we go?
@en
P2093
McFarland HF
Stürzebecher CS
P2860
P304
P356
10.1038/NI0901-785
P407
P50
P577
2001-09-01T00:00:00Z